
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Molecular Epidemiology Unit, Centre for Epidemiology and Biostatistics, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds; 2 CRUK Clinical Centre, St. James's University Hospital, Leeds, United Kingdom; 3 Instituto Nacional de Salud Pública, Morelos, Mexico; and 4 Institute for Food Chemistry, University of Münster, Münster, Germany
Requests for reprints: Christopher P. Wild, Molecular Epidemiology Unit, Centre for Epidemiology and Biostatistics, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, United Kingdom. Phone: 44-113-3436602; Fax: 44-113-3436603. E-mail: c.p.wild{at}leeds.ac.uk
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Maize is the third most important cereal grain for human consumption in the world after wheat and rice and is a staple food in many regions. Mexico has one of the highest per capita consumptions of maize in the world, with a total production of
15 million tons per annum. According to Food and Agriculture Organization data for the year 2005, per capita maize consumptions were 70, 104, and 120 kg in the United States, South Africa, and Mexico, respectively (7). In Mexico, 60% of the total maize production will be used for human consumption, and an average consumption of tortillas (the most common maize-based food) can be as high as 325 g/d per person (8).
Fumonisins have been found in maize samples worldwide, with levels of FB1 reaching >10 ppm in the United States and >100 ppm in parts of Africa (1). In Henan, China, FB1 levels of 18 to 155 ppm were reported in heavily mold-contaminated grains (3). In the former Transkei region of South Africa, human exposures to FB1 were calculated to be between 14 and 440 µg/kg body weight/d, whereas the exposure for consumers of maize in the United States was estimated as only 0.08 µg/kg body weight/d (1). Recognizing the carcinogenicity of FB1, and based on the observed renal toxicity in rats, the WHO has recommended a provisional maximum tolerable daily intake of 2 µg/kg body weight (9) for FB1, FB2, and FB3 alone or in combination. Several countries worldwide have introduced recommended levels to control human exposure, with maximum levels set by the Food and Drug Administration at 4 ppm (total FB1, FB2, and FB3) for cleaned maize intended for masa production and 2 ppm (total FB1 and FB2) in the European Union for unprocessed maize [Commission Regulation (EC) No. 1881 2006; ref. 10]. However, in many developing countries where fumonisin exposure level is high, regulation is either absent or impractical to implement.
In terms of mechanism of action, fumonisins are structural analogues of sphingoid bases and have been shown to disrupt sphingolipid biosynthesis by inhibition of ceramide synthase (11, 12). This inhibition results in complex effects on cell signaling pathways, which may explain some of the toxicology of fumonisin. In addition to its carcinogenicity, fumonisins also exert effects on the immune system (13). Fumonisin has potential for neurodevelopmental toxicity in animals and humans due to disruption of sphingomyelin formation and folate transport (6, 14).
To date, there is a limited understanding of the role of fumonisin in human disease. This is at least partly due to the absence of a validated biomarker of fumonisin exposure (15). The heterogeneous nature of maize contamination (just one or two kernels in a cob may be contaminated; ref. 16) and the uniform nature of diets in many subsistence farming communities mean that neither food analysis nor dietary questionnaires provide reliable measures of exposure. In an analogous fashion to studies of another ubiquitous mycotoxin, aflatoxin (17), a validated biomarker is a critical component in efforts to explore the cancer risk associated with exposure.
Some attempts to develop a biomarker of exposure to fumonisin have been reported. Notably, based on the above-mentioned inhibition of sphingolipid biosynthesis, an alteration in the ratio of sphinganine/sphingosine can be detected in tissues, blood, and urine following fumonisin exposure (18, 19). In animal studies, this ratio has been shown to closely reflect the dose of fumonisin administered (12, 18). However, in studies in human populations, the altered ratio appears to have limited sensitivity to detect environmental levels of exposure (19, 20). We have therefore sought to develop an alternative approach to assess exposure to fumonisin by measuring the parent compound directly in urine samples. Fumonisins are eliminated quickly after exposure with the majority excreted unmetabolized or partially hydrolyzed in feces and urine (21, 22). The methodology for this approach is based on recent advances in the measurement of fumonisin in maize and various other food matrices using high-performance liquid chromatography with fluorescence or mass spectrometric detection (23-25). A method for extraction and analysis of fumonisin in human hair has also been developed (26).
We report here a liquid chromatography-mass spectrometry (LC-MS) method to detect FB1 in human urine samples. This biomarker was strongly correlated with maize consumption, a proxy for fumonisin exposure in Mexico where maize is a dietary staple.
| Materials and Methods |
|---|
|
|
|---|
Using this approach, 75 women ages 15 to 36 years formed the three maize intake categories. For each woman, information on age, body mass index (BMI), education, occupation, birth place, and place of residence (municipality) were also available. Ethical approval for the study was obtained from the Ethics Committee of the National Institute of Public Health in Mexico, with each woman giving informed consent before participation. For each of the 75 women, a urine sample of
15 mL was available that had been stored at –80°C before urinary FB1 determination at the University of Leeds.
Urinary FB1 Analysis
Chemicals. FB1 was purchased from Sigma-Aldrich. Deuterium-labeled FB1 (FBd6) was isolated from F. verticillioides culture material as described previously (29). Both FB1 and FBd6 were initially dissolved in acetonitrile/water (1:1, v/v) as a stock solution and then were diluted in methanol/water (1:1, v/v) to serve as standard and internal standard, respectively, for the analytical work as this resulted in sharper peaks on the liquid chromatograph.
Urine Preparation. Urine samples (10 mL) were thawed and centrifuged at 675 x g at 4°C to remove particulate matter. The urines were subsequently diluted with an equal volume of distilled water and internal standard FBd6 (2 ng) was added. The sample was then slowly (1 mL/min) loaded onto a 3CC Oasis MAX cartridge (Waters), which had been preconditioned with 2 mL methanol/water (1:1, v/v). After washing the cartridge with 2 mL of 5% ammonium hydroxide in water and 2 mL of 100% methanol consecutively, the FB1 was eluted with 2 mL of 2% formic acid in methanol at a flow rate of 1 mL/min. The eluate was dried in vacuum and reconstituted in 200 µL methanol/water (1:1, v/v) before injection onto high-performance liquid chromatography.
One negative and two positive quality controls were processed along with each batch of human urine samples. The quality controls comprised a UK urine sample either spiked or not with 2 ng FB1 and 2 ng FBd6.
LC-MS Analysis. A Waters 2795 high-performance liquid chromatography separation module (Waters) was coupled online with a Quattro Micro MS system (Waters) using electrospray ionization (capillary voltage 3 kV, cone voltage 40 V, and source temperature 140°C). A Luna C18 column (50 x 4.6 mm ID, 5 µm Phenomenex) was used for separation with a gradient starting with 75% mobile phase (A) water/acetonitrile/formic acid at 90%:10%:0.1% and 25% mobile phase (B) water/acetonitrile/formic acid at 10%:90%:0.1%, reaching 25% A and 75% B over 11 min. The flow rate was 1 mL/min. The reconstituted sample (25 µL) was injected onto the column. One fifth of the volume of the post-column eluate was directed into the electrospray ion source. The mass spectrometer was operating in the selective ion monitoring mode with two functions, first with one channel ion scan at m/z 722.3 (M + H+ for FB1) and second with one channel ion scan at m/z 728.2 (M + H+ for FBd6). The FB1 concentration was quantified using Masslynx 4.0 (Micromass) software based on a standard curve using the internal standard, run daily. FBd6 contained a small amount (6%) of FB1, and this was subtracted when calculating the levels of urinary FB1. The standard curve was linear from 1 to 50 ng FB1/mL, equivalent to 20 to 1,000 pg/mL urine. In spiked human urine samples, the lowest FB1 concentration to give a clearly measurable peak with a signal-to-noise ratio >3, a recovery of
100%, and a coefficient of variation of <20% was 20 pg/mL. Duplicate injections of each sample extract were done.
Urinary Creatinine
Urinary creatinine level was determined using the alkaline-picrate method (30) with minor modifications to adapt the assay to a 96-well plate format. Urinary creatinine (mg/dL urine) was used to adjust the fumonisin concentration to control for interindividual variation in urine concentration.
Statistical Analysis
Urinary FB1 levels were not normally distributed and values were therefore natural log transformed for statistical comparison between the different maize consumption groups using ANOVA and for correlation and regression analyses. Urine samples below the LOD (20 pg FB1/mL urine) were assigned a value of half the LOD (that is, 10 pg/mL) for statistical analysis. The data are presented in two ways: pg FB1/mL urine and pg FB1/mg creatinine. These two approaches gave similar overall results. A trend test was used to test the linearity between maize intake and urinary FB1. Multiple linear regression modeling was used to investigate the contribution of maize intake to urinary FB1 while considering other factors, such as age, education (a possible proxy of socioeconomic status), and place of residence. STATA version 9.0 was used for the analysis.
| Results |
|---|
|
|
|---|
|
|
2 = 17.3; P < 0.001; Table 2
). Only one subject in the high maize consumption group had nondetectable urinary FB1. The geometric mean urinary FB1 level was strongly correlated with maize consumption (Ptrend = 0.001). Individuals in the high maize intake group had 3-fold higher mean urinary FB1 levels compared with the "low intake" group (F = 7.3; P = 0.0015). A similar trend is observed when creatinine-adjusted urinary FB1 levels are compared among the three groups (see Table 2).
|
|
| Discussion |
|---|
|
|
|---|
Tortillas are the major source of maize in the Mexican diet and can account for
70% of the daily caloric intake in rural areas (31). The average tortilla consumption in this cohort of women from Morelos was around six tortillas per day, a figure close to the national average of seven (32). Therefore, tortillas would most likely be the major source of fumonisin exposure, and this was the reason for establishing the three maize consumption categories primarily based on tortilla consumption. The observation from this study that the daily consumption of tortillas was strongly correlated with urinary FB1 is therefore consistent with this measure reflecting fumonisin exposure. However, it should be noted that we did not have a direct measure of fumonisin intake, and as such, we cannot conclude that there is a quantitative relationship between fumonisin intake and urinary FB1. As only spot urines were available, we measured urinary creatinine to adjust for expected variations in urinary volume and FB1 levels were still strongly correlated with maize consumption when expressed in this way. In addition, we measured only FB1 in this study, although the tortillas are likely to also contain FB2 and FB3 as well as the hydrolyzed forms of FB1, FB2, and FB3 following the process of nixtamalization (33). Future consideration of other urinary fumonisins would be of value both in terms of exposure assessment but also to explore the absorption of different fumonisins in exposed people.
FB1 was detectable in 75% of the urine samples. Of the women in the high and medium maize intake groups, 96% and 80%, respectively, contained a detectable level of urinary FB1; levels were 3-fold higher in the "high intake" than the "low intake" group. The correlation between maize intake and urinary FB1 was seen after adjustment for other factors such as age, education (also serves as a proxy of socio-economic status), occupation, and residence.
Although mean urinary FB1 was correlated with maize intake at the group level, there is clearly great interindividual variation within the groups. There are several possible explanations for this: the well-known heterogeneous contamination of maize may lead to a dissociation of maize consumption and fumonisin exposure (16); variations in food preparation methods can affect fumonisin level (34, 35); other sources of fumonisin exposure are not considered in the categorization of participants in this study; finally, due to the expected short half-life of urinary FB1 (22), the data will reflect recent exposure (that is, the previous 24- to 48-h exposure), whereas the food frequency questionnaire is summarizing typical maize consumption over the previous year.
Animal studies suggested that the majority of the FB1 ingested is excreted in feces, with only
0.4% to 2% excreted in urine in rats, pigs, and nonhuman primates (22, 36-38). Assuming an average daily urine volume of 1.5 L and urinary excretion of 1% FB1 (based on the pig and nonhuman primate data cited above), the mean level of 147 pg/mL urine in the high maize intake group would translate into a daily FB1 exposure of 368 ng/kg body weight (range, 0-23,311 ng/kg body weight/d) for an adult of body weight of 60 kg. This estimate has certain limitations due to the uncertainty concerning urinary FB1 excretion in humans. However, some of the subjects in the study do have estimated exposure levels of >2 µg/kg body weight, the current WHO provisional maximum tolerable daily intake for fumonisin. The calculated exposure is in a similar range to estimates of intake at the Texas-Mexican border where the women in the highest quartile of intake were estimated to consume 650 to 9,441 ng fumonisin/kg body weight/d (6). Our estimate is somewhat higher than intake levels estimated in the United States but lower than those in South Africa (39).
It is noteworthy that the nixtamalization process by which maize is boiled in a lime solution to produce masa for tortillas is known to reduce the fumonisin level up to 80% (34, 40, 41). According to De la Campa et al.'s (34) observation in four small scale tortilla companies, FB1 can be reduced to undetectable levels in tortillas made from maize contaminated with FB1 at 0.6 to 1.6 ppm. Therefore, intake of FB1 might be expected to be at a much higher level if maize is consumed in ways other than from tortillas.
In the multivariate model, age and place of residence were also associated with urinary FB1. Younger women had higher FB1 levels, but it is unclear whether this is due to a difference in maize intake or perhaps indicative of lower income and poorer diet in younger women. The current result also indicates that residents of an urban county may have lower levels of exposure to fumonisin than those living in the suburban municipalities, but the reasons for this could not be investigated in this study.
In summary, a LC-MS method for the detection of urinary FB1 has been developed with sufficient sensitivity to analyze urine samples from subjects exposed to fumonisin in Mexico. More than half the study population had detectable urinary FB1 and both the frequency of positive samples and the levels were associated with maize-based tortilla consumption. This biomarker therefore holds promise for future epidemiologic studies seeking to elucidate the role of these environmental toxins in human disease risk, including cancer and neural tube defects.
| Footnotes |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 9/ 7/07; revised 12/10/07; accepted 12/14/07.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |